his correct in the dilution but coming in as a biotech it’s important we minimise the amount they raise at phase 1 because the rise is exponential on success which is a reflection of recent GLP success. The smaller the market cap in this case a 25 million market cap with 7.4 million in cash, peers in this space are all trading at around 100 million markets but NYR is very unique in that it can be dosed for many days without the neurotoxicity of a glutamate inhibitor. It’s a new drug class and no other drug can do what it does as it’s the first of its kind
There was an institutional write up that was done and this was stated back then and so far it has been 100 percent correct in their findings and that’s why they pass phase 1 coming up shortly then phase 2 is in the bag based off the pharmacology of the drug in previous studies in glutamate antagonist. So it’s got some significant rerating coming up:
NYR Price at posting:
14.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)